Chemo plus immunotherapy for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread far from the lung).
- You have not had any chemotherapy or other cancer treatment for this lung cancer.
- You are at least 18 years old and able to do your daily activities without much help (ECOG 0-1).
- Your kidney, liver, and blood cell counts are within certain limits (checked by a blood test).
- You do not have active or untreated brain metastases, significant bleeding risks, or major heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial tests a new combination of two drugs—a type of chemotherapy called paclitaxel (in a special micelle formulation, like a tiny carrier) plus an immunotherapy called ivonescimab—for people whose small-cell lung cancer has returned after standard treatment. The goal is to see if this combo can help shrink tumors and slow the cancer's growth.
Hear when a new Extensive Stage Lung Small Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.